{"name":"Fujian Shengdi Pharmaceutical Co., Ltd.","slug":"fujian-shengdi-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"fujianshengdi.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"All-in-one parenteral nutrition","genericName":"All-in-one parenteral nutrition","slug":"all-in-one-parenteral-nutrition","indication":"Nutritional support in patients unable to tolerate enteral feeding","status":"phase_3"},{"name":"HRS-5632","genericName":"HRS-5632","slug":"hrs-5632","indication":"Other","status":"phase_2"},{"name":"HRS-9057 injection set","genericName":"HRS-9057 injection set","slug":"hrs-9057-injection-set","indication":"Other","status":"phase_2"},{"name":"HRS-9563 Injection","genericName":"HRS-9563 Injection","slug":"hrs-9563-injection","indication":"Other","status":"phase_2"},{"name":"HRS5580","genericName":"HRS5580","slug":"hrs5580","indication":"Other","status":"phase_2"},{"name":"HRS9432","genericName":"HRS9432","slug":"hrs9432","indication":"Other","status":"phase_2"},{"name":"HRS9531 Tablet","genericName":"HRS9531 Tablet","slug":"hrs9531-tablet","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"HR20013 for injection；dexamethasone","genericName":"HR20013 for injection；dexamethasone","slug":"hr20013-for-injection-dexamethasone","indication":"Inflammatory and allergic conditions","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"HR19006","genericName":"HR19006","slug":"hr19006","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"All-in-one parenteral nutrition","genericName":"All-in-one parenteral nutrition","slug":"all-in-one-parenteral-nutrition","phase":"phase_3","mechanism":"All-in-one parenteral nutrition provides complete macronutrient and micronutrient support intravenously for patients unable to eat or absorb nutrients orally.","indications":["Nutritional support in patients unable to tolerate enteral feeding","Post-operative nutritional support","Critical illness requiring total parenteral nutrition"],"catalyst":""},{"name":"HR20013 for injection；dexamethasone","genericName":"HR20013 for injection；dexamethasone","slug":"hr20013-for-injection-dexamethasone","phase":"phase_3","mechanism":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.","indications":["Inflammatory and allergic conditions","Cerebral edema","Adrenocortical insufficiency","Shock (septic, anaphylactic)","Autoimmune disorders"],"catalyst":""},{"name":"HRS-5632","genericName":"HRS-5632","slug":"hrs-5632","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-9057 injection set","genericName":"HRS-9057 injection set","slug":"hrs-9057-injection-set","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR19006","genericName":"HR19006","slug":"hr19006","phase":"phase_3","mechanism":"HR19006 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"HRS-9563 Injection","genericName":"HRS-9563 Injection","slug":"hrs-9563-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS5580","genericName":"HRS5580","slug":"hrs5580","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS9432","genericName":"HRS9432","slug":"hrs9432","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS9531 Tablet","genericName":"HRS9531 Tablet","slug":"hrs9531-tablet","phase":"phase_3","mechanism":"HRS9531 Tablet's mechanism of action is not publicly available.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxORVFEdVh2b3ZPNnhVVlU0Z0xzdlpnOTZCbi1ZSUFhM2lWMnoya1IySEtiRVB0Tl9UV3ozQ3M5T0pRZ0xjRnpCR1RjYUt4ekd0YW5OT29YcjAxM3FObF9fRmZfMWstc2lLdkNsNi1ZVkQ1aHlMWFZnTThNQmpYcmVQQzhscTZXcFBLRnZuQWxjR0M2WDVfMlBjWnRXcG1zSGlyREZzYzV4VWFOS1NGSEpaOWQ1ck9vRUVQaWhSRFZGQ0YyS1BfMkVPTlhpX3NtS0Frd0tOdEhxTWNOSHlpNUVJVWd2SWNJQzZiTU9VQg?oc=5","date":"2024-10-16","type":"pipeline","source":"GlobeNewswire","summary":"80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - GlobeNewswire","headline":"80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":4,"phase_2":5},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}